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Toxicokinetic studies are essential in clinical and forensic toxicology to understand drug-drug 
interactions, influence of individual polymorphisms, and elimination routes, as well as to evaluate 
targets for toxicological screening procedures. An N-(2-methoxybenzyl)-substituted 
phenethylamines (NBOMe analogues) intake has been associated with severe adverse reactions 
including deaths. 1-(1-Benzofuran-5-yl)-N-[(2-methoxyphenyl)methyl]propan-2-amine (5-APB-
NBOMe), 2-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b′]difuran-4-yl)-N-[(5-chloro-2-
ethoxyphenyl)methyl]ethan-1-amine (2C-B-FLY-NB2EtO5Cl), and 2-(8-bromo-2,3,6,7-
tetrahydrobenzo[1,2-b:4,5-b′]difuran-4-yl)-N-[(2-methoxyphenyl)methyl]ethan-1-amine (2C-
BFLY-NBOMe) are three emerging NBOMe analogues, which have encountered on the drugs of 
abuse market. So far, their toxicokinetic data are completely unexplored.  
Methods  
The study included mass spectrometry-based identification of phase I and II metabolites following 
exposure to the terminally differentiated human hepatocellular carcinoma cells (HepaRG). The 
determination of enzymes involved in the major phase I/II metabolic steps and determination of 
plasma protein binding (PPB) was done. Finally, the evaluation of the toxicological detectability by 
different hyphenated mass spectrometry techniques in standard urine screening approaches (SUSAs) 
was investigated.  
Results  
The compounds were extensively metabolized in HepaRG cells mainly via O-dealkylation, 
hydroxylation, glucuronidation, and combinations thereof. CYP1A2, 2D6, 2C8, 2C19, and 3A4, were 
involved in the initial reactions of all investigated compounds. Glucuronidation of the phase I 
metabolites – when observed - was mainly catalyzed by UGT1A9. The PPB of all compounds was 
determined to be > 85%. Only the high-resolution mass spectrometry-based SUSA allowed detection 





The toxicokinetic data provided by this study will help forensic and clinical toxicologists to reliably 










The emergence of new psychoactive substances (NPS) has attracted the attention of various 
stakeholders concerned with the impact of drug abuse, social and individual harms and public health. 
The diverse nature of these particular substances adds significant challenges to forensic toxicology 
and groups include synthetic cannabinoid receptor agonists, synthetic cathinones, phenethylamines, 
and many others [1, 2]. A specific set of phenethylamines is represented by additional modification 
of the side chain nitrogen atom commonly referred to as N-(2-methoxybenzyl)-substituted 
phenethylamines (NBOMes), which have been associated with significant toxicity [3-10]. They are 
usually administrated via blotting papers [6] although drops for nasal application have also been 
reported [11]. Adverse effects include tachycardia, hypertension, and aggressive behavior [12] but 
other clinical features also associated with serotonergic toxicity have been reported including 
seizures, hyperthermia, and vasoconstriction [3]. NBOMes are highly potent agonists at various 5-
HT receptor subtypes including HT2A/2B/2C/1A [3, 13]. 2-(8-Bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-
b′]difuran-4-yl)ethan-1-amine (2C-B-FLY) belongs to a representative of the so-called “FLY” series 
that has been shown to be a potent 5-HT2A-receptor agonist [e.g. 14, 15, 16]. In Europe, the detection 
of 2C-B-FLY has been reported to the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) first in 2007 [17]. Oral doses reported for some FLY compounds ranged from 0.5-20 
mg [18]. 2-(8-Bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b′]difuran-4-yl)-N-[(2-
methoxyphenyl)methyl]ethan-1-amine (2C-B-FLY-NBOMe), i.e. the NBOMe derivative of 2C-B-
FLY, has also been shown to activate the 5-HT2A receptor [e.g. 14, 19] and thus suspected to result 
in psychoactive effects in humans. In more recent years, the detection of an unusual NBOMe 
derivative of 5-(2-aminopropyl)benzofuran (5-APB) was reported, namely 1-(1-benzofuran-5-yl)-N-
[(2-methoxyphenyl)methyl]propan-2-amine (5-APB-NBOMe) [20-22]. The third NBOMe derivative 
featured in the present investigation was 2-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b′]difuran-4-
yl)-N-[(5-chloro-2-ethoxyphenyl)methyl]ethan-1-amine (2C-B-FLY-NB2EtO5Cl) that has to date 





As NBOMe are known to be extensively metabolized [e.g. 23], metabolism studies are essential to 
understand drug-drug interactions, influence of individual polymorphisms, elimination routes, and 
for developing toxicological screening procedures [4-6, 23]. Therefore, the aims of the present study 
were tentative identification of their phase I and II metabolites by means of hyphenated high-
resolution mass spectrometry (LC-HRMS/MS) after HepaRG exposure, determination of the 
isoenzymes involved in the major phase I and II metabolic steps, determination of plasma protein 
binding (PPB), and evaluation of their toxicological detectability by gas chromatography-mass 
spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MSn), and LC-HRMS/MS 
standard urine screening approaches (SUSAs) in rat urine after low dose administration. 
 
Materials and methods 
Chemicals, reagents, and biosamples 
5-APB-NBOMe hydrochloride was provided by the Landeskriminalamt Schleswig-Holstein (Kiel, 
Germany), 2C-B-FLY-NBOMe hydrochloride was available from previous studies [24] and 2C-B-
FLY-NB2EtO5Cl hydrochloride was from Synex Synthetics BV (Maastricht, The Netherlands). 
Isocitrate, isocitrate dehydrogenase, superoxide dismutase were obtained by Sigma-Aldrich 
(Taufkirchen, Germany), NADP+ from Biomol (Hamburg, Germany), acetonitrile (LC-MS grade), 
ammonium formate (analytical grade), formic acid (LC-MS grade), methanol (LC-MS grade), and 
all other chemicals and reagents (analytical grade) from VWR (Darmstadt, Germany). Supersomes 
containing 1 nmol/mL of human cDNA-expressed cytochrome P450 (CYP) 1A2, CYP2A6, CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (2 nmol/mL), CYP3A4, CYP3A5 (2 nmol/mL), 
FMO3 (5 mg protein/mL), or 5 mg protein/mL of human cDNA-expressed UDP-
glucuronyltransferase (UGT) 1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, 
UGT1A10, UGT2B4, UGT2B7, UGT2B10, UGT2B15, UGT2B17, and control Supersomes without 
UGT activity (UGT control), and pooled human liver microsomes (pHLM, 20 mg microsomal 
protein/mL), UGT reaction mixture solution A (25 mM UDP-glucuronic acid), and UGT reaction 




from Corning (Amsterdam, The Netherlands). The enzymes were aliquoted, snap-frozen in liquid 
nitrogen, and stored at -80 °C until use. Two-chambered Centrifree ultrafiltration devices were 
purchased from Merck Milipore (Darmstadt, Germany). Fresh human plasma samples were obtained 
from a local blood bank. Cryopreserved, differentiated HepaRG cells, 96-well plates coated with type 
I collagen, GlutaMAX, Williams Medium E, and supplement HPRG670 were obtained from Life 
Invitrogen (Darmstadt, Germany). 
 
In vitro metabolism by HepaRG 
According to Richter et al. [25], differentiated human hepatocellular carcinoma HepaRG cells at day 
0, 4 h after cell seeding were used. The cells were treated under sterile conditions using a laminar 
flow bench class II (Thermo Scientific Schwerte, Germany) and maintained in an incubator (Binder, 
Tuttlingen, Germany) at 37°C with 95 % air humidity and 5 % CO2 atmosphere. All given 
concentrations are final concentrations. The cells were seeded in a density of 72,000 cells/well (a 
100-µL aliquot cell suspension per well) in collagen-coated 96-well plates. Williams E medium 
supplemented with HPRG670, 100 U/mL penicillin, and 100 µg/mL streptomycin (thaw and seed 
medium) were used for the cell incubation. A 50-µL aliquot was removed 4 h after cell seeding from 
the plate and 50 µL thaw and seed medium containing 50 µM or 500 µM of the investigated 
compounds were added, resulting in a final concentration of 25 µM or 250 µM. Cells were incubated 
for 24 h. For analysis of metabolites, supernatants from the well plates were collected. A 50-µL 
aliquot each was precipitated using 50 µL acetonitrile containing 0.1 % formic acid, vortexed, cooled 
at -18°C for 30 min, and centrifuged for 2 min at 18,407 x g. Afterwards, 50 µL of the supernatant 
was transferred to an autosampler vial. A 1-µL aliquot was injected onto the LC-HRMS/MS system 
as described below. Blank incubations without substrate and control incubations without cells were 






For the monooxygenases screening, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, CYP2E1, CYP3A4, CYP3A5 (75 pmol/mL each), FMO3 (0.25 mg protein/mL), or pHLM 
(1 mg protein/mL) as positive control were incubated with substrate for 30 min at 37 °C [26]. The 
following was added to the incubation: 90 mM phosphate buffer (pH 7.4), 5 mM Mg2+, 5 mM 
isocitrate, 1.2 mM NADP+, 0.5 U/mL isocitrate dehydrogenase, and 200 U/mL superoxide dismutase. 
For the isoenzymes CYP2A6 and CYP2C9 phosphate buffer was replaced with 90 mM Tris buffer 
(pH 7.4) according to manufactures recommendations. The reaction was started by addition of 
enzyme, and stopped by addition of 50 µL ice-cold acetonitrile. Afterwards the mixture was 
centrifuged for 2 min at 18,407 x g, 50 µL of the supernatant was transferred into an autosampler 
vial, and 1 µL was injected onto the LC-HRMS/MS system for analyzing described below. All 
incubations were done in duplicates. 
 
UDP-glucuronyltransferase screening 
For the UDP-glucuronyltransferase screening, a preincubation for 30 min at 37°C using the 
monooxygenase (75 pmol/mL each) responsible for initial phase I metabolic steps identified by 
monooxygenase activity screening was done using substrate (25 µM), 90 mM phosphate buffer (pH 
7.4), 5 mM Mg2+, 5 mM isocitrate, 1.2 mM NADP+, 0.5 U/mL isocitrate dehydrogenase, and 200 
U/mL superoxide dismutase. Thereafter, 25 µg/mL alamethicin (UGT reaction mixture solution B) 
and UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, 
UGT2B7, UGT2B10, UGT2B15, UGT2B17, or UGT control (0.75 mg protein/mL, respectively) 
were added and again preincubated for 10 min at 37°C. Glucuronidation reactions were started by 
adding 2.5 mM UDP-glucuronic acid (UGT reaction mixture solution A) and additionally incubated 
for 30 min at 37 °C with a final volume of 100 µL. The reactions were stopped by adding 50 µL ice-
cold acetonitrile. After cooling for 30 min at -20 °C, the vials were centrifuged for 2 min at 18,407 x 
g. A 50-µL aliquot of the supernatant was transferred into an autosampler vial and 1 µL was injected 





Determination of plasma protein binding (PPB) 
According to published procedures [27, 28], two-chambered Centrifree ultrafiltration devices 
(molecular weight cut-off 30 kDa) were used. Three different concentrations of the investigated NPS 
were studied: 1, 2.5, and 5 µM (final concentrations). Fresh human plasma samples (450 µL) were 
spiked with 50 µL of the drug solution and incubated for 30 min at 37 °C (n=2). A 100-µL aliquot 
(global approach, GA) was transferred in a new reaction tube, mixed with 50 µL ice-cold acetonitrile, 
centrifuged for 2 min at 18,407 x g, and 100 µL of the supernatant was transferred in an autosampler 
vial (control). The remaining part of the incubation mixture was transferred into a Centrifree device 
and centrifuged at room temperature (22 °C) for 35 min at 1,600 x g. One hundred µL aliquots of the 
supernatant (SUP) and of the ultrafiltrate (UF) were mixed with 50 µL ice-cold acetonitrile. 
Supernatants were transferred into autosampler vials. All samples were analyzed by LC-HRMS/MS 
as described below. PPB was calculated as follows [27, 28]. 





, μ , μ
2
 
LogP values were calculated by ChemSketch 2016 1.1 (ACD/Labs, Toronto, Canada). 
Quantification of the NBOMe derivative in the GA was used as control as the determined 
concentration should be the same as the calculated concentration (equation 2). Thanks to this 
comparison, an adsorption of the NBOMe derivative to the Centrifree device, especially the filter 
membrane, could be excluded. 
 
LC-HRMS/MS apparatus for determination of phase I and II metabolites, 
monooxygenases and UDP-glucuronyltransferase screening, and PPB 
determination 
According to published studies [5, 29], a Thermo Fisher Scientific (TF, Dreieich, Germany) Dionex 




UltiMate 3000 RS autosampler, and a TF Accucore phenyl-hexyl column (100 mm x 2.1 mm ID, 2.6 
µm particle size) was used. The system was controlled by the TF Chromeleon software version 6.80 
and the system was coupled to a TF Q-Exactive Plus equipped with a heated electrospray ionization 
II source (HESI-II). For calibrating the system, a Positive Mode Cal Mix (Supelco, Bellefonte, PA) 
at a flow rate of 3 µL/min using a syringe pump was used. The following conditions were applied: 
The mobile phase consisted of eluent A and eluent B. Eluent A consisted of 2 mM aqueous 
ammonium formate containing formic acid (0.1 %, v/v) and eluent B consisted of an ammonium 
formate solution with acetonitrile/methanol (50:50, v/v) containing formic acid (0.1 %, v/v) and water 
(1%, v/v). The gradient and the flow rate were adjusted as follows [9]: flow rate, 0.500 mL/min; 
gradient, 0-1.0 min 99% A, 1-10 min to 50 % A, 10-11.5 min hold 1% A, 11.5-13.5 min hold 99% 
A. HESI-II conditions were as described previously [30] and modified as follows: heater temperature, 
320 °C; ion transfer capillary temperature, 320 °C; sheath gas, 60 arbitrary units (AU); auxiliary gas, 
10 AU; spray voltage, 4.00 kV, positive mode, and S-lens RF level, 50.0. For MS, a positive 
electrospray ionization (ESI) full scan mode and a targeted MS2 mode with an inclusion list 
containing the masses of interest as well activated pick others were used. For full scan data, the 
settings were as follows described: resolution, 35,000; automatic gain control (AGC) target, 1e6; 
maximum injection time (IT), 120 ms; scan range, m/z 150-900. For the MS2 mode the settings were 
as follows described: 17,500; AGC target, 2e5; maximum IT, 250 ms; isolation window, m/z 1.0; 
normalized collision energy (NCE), 35 %. For data evaluation TF Xcalibur Qual Browser software 
version 2.2 SP 1.48 was used. 
 
Detectability by standard urine screening approaches (SUSA) 
According to previous studies [31], male Wistar rats (Charles River, Sulzfeld, Germany) were used 
corresponding to German law (Bundesrepublik Deutschland, 2013 Tierschutzgesetz, 
http://www.gesetze-im-internet.de/bundesrecht/tierschg/gesamt.pdf). The administration was done 
by gastric intubation using an aqueous suspension of the investigated compounds. Doses of 0.2 mg/kg 




Sharma et al. [32]. The rats were housed in metabolic cages for 24 h, having water ad libitum. Urine 
was collected separately from the feces over a 24-hour period. Blank urine samples were collected 
before drug administration to confirm the absence of interfering compounds. After collecting the 
urine samples were used directly analyzed and the remains stored at -20°C.  
The SUSAs were performed as described previously [33, 34]. Briefly, for GC-MS, acidic hydrolysis, 
liquid-liquid extraction, and acetylation were performed before full scan GC-MS, AMDIS data 
evaluation, and library search. Urine was precipitated with acetonitrile for both liquid 
chromatography-mass spectrometry (LC-MS) approaches. The data of LC-MSn were evaluated using 
TF ToxID and library search [35] and the LC-HRMS/MS data using TF TraceFinder and library 
search [36]. 
 
Results and discussion 
ESI+ HRMS/MS fragmentation of 5-APB-NBOMe, 2C-B-FLY-NB2EtO5Cl, 2C-B-
FLY-NBOMe, and their phase I and II metabolites 
The measured accurate masses, relative intensities, calculated exact masses, elemental compositions, 
and mass deviations errors of the most abundant fragment ions of 5-APB-NBOMe, 2C-B-FLY-
NB2EtO5Cl, 2C-B-FLY-NBOMe, and all their phase I and II metabolites tentatively identified using 
HepaRG cells are given in Table 1A-C. All metabolites were tentatively identified due to their 
accurate mass and fragmentation pattern as chemical synthetized standards were not commercially 
available. Seven phase I metabolites of 5-APB-NBOMe, four of 2C-B-FLY-NB2EtO5Cl, and five of 
2C-B-FLY-NBOMe were tentatively identified. In addition, one phase II metabolite of 5-APB-
NBOMe, two of 2C-B-FLY-NB2EtO5Cl, and one of 2C-B-FLY-NBOMe were found. In the 
following, fragmentation patterns of the parent compound and tentatively identified phase I 
metabolites are exemplarily discussed for 2C-B-FLY-NBOMe. Exceptions are mentioned separately. 
The m/z of the precursor ions (PI) and the fragment ions (FI) mentioned in the following text are 




FLY-NBOMe, and their metabolites detected or identified by LC-HRMS/MS SUSA are given in 
Figure 2 and 3. In terms of SUSA, “identified” means that an MS2 spectrum was recorded and 
“detected” means that a MS2 spectrum was not recorded but the m/z in the total ion chromatogram of 
the full-scan was present at the expected RT. 
The MS2 spectrum of 2C-B-FLY-NBOMe showed characteristic NBOMe FI and characteristic non-
NBOMe FI. In case of 2C-B-FLY-NBOMe and 2C-B-FLY-NB2EtO5Cl, the non-NBOMe part was 
the FLY part and in case of 5-APB-NBOMe it was an amphetamine-type part. As already described 
by Casper et al. [23], the NBOMe part showed high abundant FIs and the non-NBOMe part showed 
lower abundant FIs, except for O-dealkylated metabolites. After O-dealkylation, the non-NBOMe 
part showed a very high abundance. The parent compound 2C-B-FLY-NBOMe with the PI at m/z 
404.0848 was not the FI with the highest abundance. The FI at m/z 267.0011 was formed by the FLY 
part and showed a low abundance. This FI showed the intact FLY part with bromine. After a loss of 
bromine, the FI at m/z 188.0828 was formed. The most abundant FI at m/z 121.0645 was formed from 
the NBOMe part. From this FI the tropylium cation at m/z 91.0540 with a medium abundance was 
created by the loss of formaldehyde. 
The phase I metabolite O-demethyl-2C-B-FLY-NBOMe (M15) with the PI at m/z 390.0692 showed 
FIs at m/z 267.0011, 188.0828, and 107.0489. The most abundant FI at m/z 267.0011 originated from 
the FLY part, as already mentioned, and abundances of the FIs reversed by a change of the NBOMe 
part. The FI at m/z 107.0489 corresponds to the O-demethylated NBOMe part. O-Demethyl-hydroxy-
2C-B-FLY-NBOMe (M16) showed the same characteristic behavior as O-demethyl-2C-B-FLY-
NBOMe (M15) for the abundances of the FIs. Due to the FI at m/z 264.9855, which originated from 
FI at m/z 388.0530 and additional elimination of water, the hydroxylation of M16 has to be located 
at the 2,3,6,7‐tetrahydrobenzo[1,2‐b:4,5‐b’]difuran part. The exact position of the hydroxy group 
could not be determined by fragmentation. Also the FI at m/z 186.0672 showed the double bond 
formed by elimination of water and could lead to stabilized by mesomerism.  
Two monohydroxylated isomers were tentatively identified. M17 showed the FIs at m/z 264.9855 




double bond and stabilizing effects due to mesomerism. The NBOMe part was not changed so the 
abundance of the FIs at m/z 264.9855 and 186.0672 was low but the most abundant FI at m/z 121.0645 
was intact. Hydroxy isomer 2 (M18) most likely occurred after an aliphatic hydroxylation which 
showed the PI at m/z 420.0797. The FI at m/z 402.0692 formed via loss of water, which resulted in a 
double bond and the intact FIs at m/z 267.0011, 188.0828, and 121.0645. The FI at m/z 121.0645 
showed the characteristic intact NBOMe part after loss of the FLY part, the FI at m/z 267.0011 
showed the intact FLY component after loss of the NBOMe part, and the FI at m/z 188.0828 showed 
the FLY part after a loss of bromine.  
One dihydroxy metabolite was tentatively identified. One of the hydroxy groups was located at the 
2,3,6,7‐tetrahydrobenzo[1,2‐b:4,5‐b’]difuran nucleus which showed the characteristic FIs at 
m/z 264.9855 and 186.0672 originated from FI at m/z 418.0641. Dihydroxy 2C-B-FLY-NBOMe 
(M19) showed a loss of water which indicated an aliphatic hydroxylation and in addition the FIs at 
m/z 121.0645 and 91.0540 were intact. All spectra showed the bromine isotope shift of +1.9979 u. 
The phase I metabolites for 5-APB-NBOMe and 2C-B-FLY-NB2EtO5Cl showed similar 
fragmentation patterns. 5-APB-NBOMe showed additionally ring openings as one of the most 
abundant metabolites similar to what has been described for 5-APB [31]. The glucuronidated 
metabolites eliminated glucuronic acid (−176.0321 u) leading to similar spectra as those of the 
respective phase I metabolites. No m/z and MS2 spectra of phase I metabolites conjugated with sulfate 
were identified meaning that no sulfates were formed or that their concentration was below the 
detection limit. 
 
Proposed in vitro metabolic pathways 
All metabolic steps following exposure of 5-APB-NBOMe to HepaRG are shown in Figure 4. The 
metabolic pathways of 5-APB-NBOMe could be summarized as follows: O-demethylation to O-
demethyl-5-APB-NBOMe (M1), oxidative ring-opening of the benzofuran ring to 3-hydroxyethyl-4-
hydroxy amphetamine-5-APB-NBOMe (M5) and 3-carboxymethyl-4-hydroxy amphetamine-5-




amphetamine-O-demethyl-5-APB-NBOMe (M2) and 3-carboxymethyl-4-hydroxy amphetamine O-
demethyl-5-APB-NBOMe (M4). 3-Hydroxyethyl-4-hydroxy amphetamine-5-APB-NBOMe 
glucuronide (M8) was the only tentatively identified phase II metabolite. Monohydroxylation formed 
hydroxy-5-APB-NBOMe (M3) as also one of the most abundant metabolites. Dihydroxy-5-APB-
NBOMe (M6) was also detected. 
The in vitro HepaRG metabolic pathways of 2C-B-FLY-NB2EtO5Cl (Figure 5) could be summarized 
as follows: Monohydroxylation to hydroxy-2C-B-FLY-NB2EtO5Cl isomer 1 (M10) and hydroxy-
2C-B-FLY-NB2EtO5Cl isomer 2 (M11) as main metabolic steps, whereby a dihydroxylation to 
dihydroxy-2C-B-FLY-NB2EtO5Cl (M12) followed (most probable position of the hydroxy group is 
given in Figure 5). The most abundant metabolite M10 was additionally conjugated with glucuronic 
acid (M14). Also, an O-deethylation was detected (M9). A second glucuronide was tentatively 
identified as O-deethyl-hydroxy-2C-B-FLY-NB2EtO5Cl glucuronide (M13). 
In vitro metabolic HepaRG pathways of 2C-B-FLY-NBOMe (Figure 6) were similar to those of 2C-
B-FLY-NB2EtO5Cl. Monohydroxylation was one of the main metabolic steps, resulting in hydroxy-
2C-B-FLY-NBOMe isomer 1 and 2 (M17, M18). Dihydroxylation was additionally observed (M19). 
Most probable position of the hydroxy group is given in Figure 6. Furthermore, O-dealkylation to O-
demethyl-2C-B-FLY-NBOMe (M15) occurred and additionally a hydroxylation to O-demethyl-
hydroxy-2C-B-FLY-NBOMe (M16). Only one phase II metabolite O-demethyl-2C-B-FLY-NBOMe 
glucuronide (M20) could be tentatively identified. 
 
Monooxygenase screening 
The monooxygenase isoenzymes catalyzing the initial metabolic steps of 5-APB-NBOMe, 2C-B-
FLY-NB2EtO5Cl, and 2C-B-FLY-NBOMe are listed in Table 2. CYP1A2 was involved in O-
dealkylation of all three derivatives. It was also catalyzing the hydroxylation of 5-APB-NBOMe and 
2C-B-FLY-NBOMe. CYP2D6 was catalyzing hydroxylations of all three investigated NPS. CYP3A4 
was only involved all metabolic phase I steps of 2C-B-FLY-NB2EtO5Cl. CYP2C8 was involved in 




dealkylation and hydroxylation of 2C-B-FLY-NB2EtO5Cl. The CYP enzyme catalyzing the ring 
opening of 5-APB-NBOMe could not be evaluated due to low metabolic formation rate in the initial 
monooxygenases activity screening.  
 
UDP-glucuronyltransferase screening 
The catalyzing UDP-glucuronyltransferase for glucuronidation of phase I metabolites are listed in 
Table 3. Glucuronidation was exclusively catalyzed by UGT1A9, except for 2C-B-FLY-NB2EtO5Cl, 
where UGT1A7 was additionally involved. The catalyzing UGT enzyme for glucuronidation of 3-
hydroxyethyl-4-hydroxy amphetamine-5-APB-NBOMe (M5) could not be evaluated due to low 
metabolic formation rate of M5 in the initial monooxygenases activity screening. 
 
Determination of plasma protein binding (PPB) 
The lipophilicity of a compound is an important physicochemical property and associated with 
intermolecular interactions between plasma proteins and substrates [37, 38]. For all investigated NPS, 
the PPBs slightly increased by increasing plasma concentrations. These were unexpected findings as 
the PPB was expected to decrease with increasing plasma concentration [37, 38]. A possible 
explanation for this might be that the compounds exclusively bind to albumin or alpha-1-acid 
glycoprotein at low concentrations. At higher concentrations the investigated compounds may also 
bind to other plasma proteins such as globulins. The highest PPB was found for 2C-B-FLY-
NB2EtO5Cl, which also had the highest logP value and thus the highest lipophilicity. 5-APB-
NBOMe and 2C-B-FLY-NBOMe also showed a high PPB and also an increasing PPB by increasing 
concentrations. A list of the PPB at the different concentrations are given in Table 4. 
 
Detectability using standard urine screening approaches (SUSA) 
According to Sharma and McNeill [32] the administrated dosages were calculated to be 0.02 mg/kg 




corresponded to human doses of 0.003 and 0.03 mg/kg BW, respectively, which are expected to be 
comparatively low [18, 13]. GC-MS, LC-MSn, and LC-HRMS/MS SUSAs were used to investigate 
the toxicological detectability. Via GC-MS, neither parent compounds nor metabolites could be 
detected. All tentatively identified and detected metabolites using the LC-MSn approach are listed in 
Table 5. No parent compounds were identified or detected and only two metabolites of 5-APB-
NBOMe were found (M5 and M7). For 2C-B-FLY-NB2EtO5Cl no metabolites were detected. M17 
was the only detected 2C-B-FLY-NBOMe metabolite. Using the LC-HRMS/MS approach, no parent 
compounds were detected. Spectra of 5-APB-NBOMe and all tentatively identified metabolites are 
given in Figure 2. In case of 2C-B-FLY-NB2EtO5Cl and 2C-B-FLY-NBOMe, metabolites were only 
detected but not identified. However, these metabolites are expected to be identified in intoxication 
cases and are therefore recommended as targets for detection of overdoses. Spectra of 2C-B-FLY-
NB2EtO5Cl and 2C-B-FLY-NBOMe and all their detected metabolites are given in Figure 3. In 
summary, the LC-HRMS/MS SUSA seems to be the most promising procedure for a toxicological 
urine screening for 5-APB-NBOMe, 2C-B-FLY-NB2EtO5Cl, and 2C-B-FLY-NBOMe by using 
metabolites as screening targets. 
 
Conclusions 
The NPS 5-APB-NBOMe, 2C-B-FLY-NB2EtO5Cl, and 2C-B-FLY-NBOMe were found to be 
extensively metabolized in HepaRG cells mainly via O-dealkylation, hydroxylation, glucuronidation, 
and combinations thereof. Due to the structural similarity of the studied NPS, the same 
monooxygenase isoenzymes were involved in the initial metabolic reactions, namely CYP1A2, 2D6, 
2C8, 2C19, and 3A4. Glucuronidation of the phase I metabolites was mainly catalyzed by UGT1A9 
for all investigated compounds. The tentatively identified in vitro metabolites could be used as targets 
for urinary toxicological screening approaches. From the investigated SUSAs, only the HRMS/MS-
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Figure 2. HRMS/MS spectra, structures, and predominate fragmentation patterns of 5-APB-NBOMe 
and its metabolites identified (I) by LC-HRMS/MS standard urine screening approach (SUSA) in 
very low dose (0.02 mg/kg body weight) and low dose (0.2 mg/kg body weight) rat urine (N.D. = not 






Figure 3. HRMS/MS spectra, structures, and predominate fragmentation patterns of 2C-B-FLY-
NB2EtO5Cl, 2C-B-FLY-NBOMe, and their metabolites identified (I) or detected (D) by LC-
HRMS/MS standard urine screening approach (SUSA) in very low dose (0.02 mg/kg body weight) 
and low dose (0.2 mg/kg body weight) rat urine (N.D. : not detected). Metabolites arranged according 






Figure 4. In vitro metabolic pathways of 5-APB-NBOMe identified using HepaRG cells by means 
































Figure 5. In vitro metabolic pathways of 2C-B-FLY-NB2EtO5Cl identified using HepaRG cells by 























Figure 6. In vitro metabolic pathways of 2C-B-FLY-NBOMe identified using HepaRG cells by 
means of LC-HRMS/MS. 
  
Table 1A. List of 5-APB-NBOMe and its phase I and II metabolites identified in HepaRG cell incubations together with their metabolic reactions, precursor ion mass (PI) recorded in 
MS1, the corresponding characteristic fragment ions (FI) and their intensity in MS2, the calculated exact masses, the corresponding elemental composition, the deviation of the measured 
from the calculated masses given as errors in ppm, the retention times (RT) in minutes (min), and the peak area. The metabolites were sorted by mass and RT. 
Metabolite 
ID 















         
Parent 
compound 
 PI at m/z 296.1637 
 
FI at m/z 159.0803 
FI at m/z 121.0649 







PI at m/z 296.1638 
 
FI at m/z 159.0801 
FI at m/z 121.0645 












M1 O-Dealkylation PI at m/z 282.1483 
 
FI at m/z 176.1070 
FI at m/z 159.0804 
FI at m/z 131.0492 








PI at m/z 282.1482 
 
FI at m/z 176.1065 
FI at m/z 159.0801 
FI at m/z 131.0489 














M2 O-Dealkylation +  
ring-opening + hydroxylation 
PI at m/z 302.1748 
 
FI at m/z 284.1648 
FI at m/z 164.1069 
FI at m/z 121.0650 








PI at m/z 302.1743 
 
FI at m/z 284.1638 
FI at m/z 164.1065 
FI at m/z 121.0645 
















M3 Hydroxylation  PI at m/z 312.1587 
 
FI at m/z 159.0803 
FI at m/z 137.0598 







PI at m/z 312.1587 
 
FI at m/z 159.0801 
FI at m/z 137.0594 












M4 O-Dealkylation +  
ring-opening + carboxylation 
PI at m/z 316.1541 
 
FI at m/z 210.1124 
FI at m/z 193.0857 






PI at m/z 316.1536 
 
FI at m/z 210.1119  
FI at m/z 193.0855 















FI at m/z 147.0803  




FI at m/z 147.0801  





M5 Ring-opening + hydroxylation PI at m/z 316.1897 
 
FI at m/z 299.1637 
FI at m/z 281.1525 
FI at m/z 179.1065 
FI at m/z 161.0958 
FI at m/z 121.0650 










PI at m/z 316.1899 
 
FI at m/z 299.1635 
FI at m/z 281.1530 
FI at m/z 179.1062 
FI at m/z 161.0957 
FI at m/z 121.0645 


















M6 Dihydroxylation PI at m/z 328.1539 
 
FI at m/z 310.1430 
FI at m/z 137.0597 







PI at m/z 328.1536 
 
FI at m/z 310.1431 
FI at m/z 137.0594 












M7 Ring-opening + carboxylation PI at m/z 330.1695 
 
FI at m/z 313.1430 
FI at m/z 295.1327 
FI at m/z 175.0752 
FI at m/z 147.0804 
FI at m/z 121.0650 










PI at m/z 330.1692 
 
FI at m/z 313.1428 
FI at m/z 295.1323 
FI at m/z 175.0750 
FI at m/z 147.0801 
FI at m/z 121.0645 


















M8 Ring-opening + hydroxylation 
+ glucuronidation  
PI at m/z 492.2230 
 
FI at m/z 316.1905 
FI at m/z 299.1641 
FI at m/z 179.1065 
FI at m/z 121.0650 









PI at m/z 492.2217 
 
FI at m/z 316.1899 
FI at m/z 299.1635 
FI at m/z 179.1062 
FI at m/z 121.0645 




















Table 1B: List of 2C-B-FLY-NB2EtO5Cl and its phase I and II metabolites identified in HepaRG cell incubations together with their metabolic reactions, precursor ion mass (PI) recorded 
in MS1, the corresponding characteristic fragment ions (FI) and their intensity in MS2, the calculated exact masses, the corresponding elemental composition, the deviation of the measured 
from the calculated masses given as errors in ppm, the retention times (RT) in minutes (min), and the peak area. The metabolites were sorted by mass and RT. 
Metabolite ID Metabolic reaction Characteristic ions 
measured accurate 
masses, u 












         
Parent 
compound 
 PI at m/z 452.0626 
 
FI at m/z 267.0014 
FI at m/z 188.0830 
FI at m/z 169.0413 








PI at m/z 452.0614 
 
FI at m/z 267.0011 
FI at m/z 188.0828 
FI at m/z 169.0411 














M9 O-Dealkylation PI at m/z 424.0306 
 
FI at m/z 267.0013 
FI at m/z 188.0830 







PI at m/z 424.0302 
 
FI at m/z 267.0011 
FI at m/z 188.0828 












M10 Hydroxylation isomer 1 PI at m/z 468.0574 
 
FI at m/z 450.0466 
FI at m/z 264.9857 
FI at m/z 186.0676 
FI at m/z 169.0413 









PI at m/z 468.0563 
 
FI at m/z 450.0458 
FI at m/z 264.9855 
FI at m/z 186.0672 
FI at m/z 169.0411 
















M11 Hydroxylation isomer 2 PI at m/z 468.0573 
 
FI at m/z 450.0461 
FI at m/z 267.0011 
FI at m/z 188.0831 
FI at m/z 169.0414 









PI at m/z 468.0563 
 
FI at m/z 450.0458 
FI at m/z 267.0011 
FI at m/z 188.0828 
FI at m/z 169.0411 






























FI at m/z 466.0411 
FI at m/z 448.0304 
FI at m/z 264.9858 
FI at m/z 186.0675 
FI at m/z 169.0414 








FI at m/z 466.0407 
FI at m/z 448.0302 
FI at m/z 264.9855 
FI at m/z 186.0672 
FI at m/z 169.0411 













M13 O-Dealkylation +  
hydroxylation + 
glucuronidation 
PI at m/z 616.0583 
 
FI at m/z 440.0267 
FI at m/z 422.0154 
FI at m/z 264.9856 
FI at m/z 186.0678 








PI at m/z 616.0569 
 
FI at m/z 440.0251 
FI at m/z 422.0146 
FI at m/z 264.9855 
FI at m/z 186.0672 

















M14 Hydroxylation +  
glucuronidation 
PI at m/z 644.0880 
 
FI at m/z 468.0573 
FI at m/z 450.0471 
FI at m/z 264.9864 
FI at m/z 186.0679 
FI at m/z 169.0413 









PI at m/z 644.0881 
 
FI at m/z 468.0563 
FI at m/z 450.0458 
FI at m/z 264.9855 
FI at m/z 186.0672 
FI at m/z 169.0411 























Table 1C. List of 2C-B-FLY-NBOMe and its phase I and II metabolites identified in HepaRG cell incubations together with their metabolic reactions, precursor ion mass (PI) recorded 
in MS1, the corresponding characteristic fragment ions (FI) and their intensity in MS2, the calculated exact masses, the corresponding elemental composition, the deviation of the measured 
from the calculated masses given as errors in ppm, the retention times (RT) in minutes (min), and the peak area. The metabolites were sorted by mass and RT. 
Metabolite 
ID 















         
Parent 
compound 
 PI at m/z 404.0843 
 
FI at m/z 325.1668 
FI at m/z 267.0008 
FI at m/z 188.0829 
FI at m/z 121.0649 









PI at m/z 404.0848 
 
FI at m/z 325.1665 
FI at m/z 267.0011 
FI at m/z 188.0828 
FI at m/z 121.0645 
















M15 O-Dealkylation PI at m/z 390.0696 
 
FI at m/z 267.0010 
FI at m/z 188.0834 







PI at m/z 390.0692 
 
FI at m/z 267.0011 
FI at m/z 188.0828 












M16 O-Dealkylation + 
hydroxylation 
PI at m/z 406.0635 
 
FI at m/z 388.0530 
FI at m/z 300.0223 
FI at m/z 264.9851 
FI at m/z 186.0672 









PI at m/z 406.0641 
 
FI at m/z 388.0536 
FI at m/z 300.0224 
FI at m/z 264.9855 
FI at m/z 186.0672 
















M17 Hydroxylation isomer 1 PI at m/z 420.0797 
 
FI at m/z 264.9851 
FI at m/z 186.0673 
FI at m/z 121.0650 








PI at m/z 420.0797 
 
FI at m/z 264.9855 
FI at m/z 186.0672 
FI at m/z 121.0645 




























FI at m/z 402.0692 
FI at m/z 267.0009 
FI at m/z 188.0828 
FI at m/z 121.0648 







FI at m/z 402.0692 
FI at m/z 267.0011 
FI at m/z 188.0828 
FI at m/z 121.0645 











M19 Dihydroxylation  PI at m/z 436.0745 
 
FI at m/z 418.0638 
FI at m/z 400.0577 
FI at m/z 264.9850 
FI at m/z 186.0671 
FI at m/z 121.0648 










PI at m/z 436.0746 
 
FI at m/z 418.0641 
FI at m/z 400.0536 
FI at m/z 264.9855 
FI at m/z 186.0672 
FI at m/z 121.0645 


















M20 O-Dealkylation + 
glucuronidation 
PI at m/z 566.1003  
 
FI at m/z 390.0682  
FI at m/z 267.0006  
FI at m/z 188.0831  







PI at m/z 566.1010  
 
FI at m/z 390.0692 
FI at m/z 267.0011 
FI at m/z 188.0828 















Table 2. Results of the monooxygenases activity screening 
 
Metabolite ID Investigated NPS Metabolic reaction Isoenzymes 
M1 5-APB-NBOMe O-Dealkylation CYP1A2 
M3 5-APB-NBOMe Hydroxylation CYP1A2, 2D6, 2C8 
M9 2C-B-FLY-NB2EtO5Cl O-Dealkylation CYP1A2, 2C19, 3A4 
M10 2C-B-FLY-NB2EtO5Cl Hydroxylation isomer 1 CYP2C19, 3A4 
M11 2C-B-FLY-NB2EtO5Cl Hydroxylation isomer 2 CYP2C19, 2D6, 3A4 
    
M15 2C-B-FLY-NBOMe O-Dealkylation CYP1A2, 2C8 
M17 2C-B-FLY-NBOMe Hydroxylation isomer 1 CYP1A2, 2C8, 2D6 





Table 3. Results of the UDP-glucuronyltransferase activity screening 
 
Metabolite ID Investigated NBOMe Metabolic reaction Isoenzymes 
M13 2C-B-FLY-NB2EtO5Cl O-Dealkylation + hydroxylation + glucuronidation UGT1A7, 1A9 
M14 2C-B-FLY-NB2EtO5Cl hydroxylation + glucuronidation UGT1A9 





Table 4. Determined plasma protein binding (PPB) of 5-APB-NBOMe, 2C-B-FLY-NB2EtO5Cl, and 
2C-B-FLY-NBOMe at three different concentrations (1, 2.5, and 5 µM) and their calculated logP 
values.  
 
Compound Concentration, µM PPB, % logP 
5-APB-NBOMe 1 86 4.3 
 2.5 89  
 5 93  
 
2C-B-FLY-NB2EtO5Cl 1 87 5.3 
 2.5 99  
 5 99  
 
2C-B-FLY-NBOMe 1 91 4.1 
 2.5 96  
 5 97  
 
 
Table 5.  
List of compounds detected or identified by LC-MSn standard urine screening approach after administration of 0.02 or 0.2 mg/kg body weight in rat urine 
together with their metabolic reaction, precursor ion mass (PI) recorded in MS1, the corresponding characteristic fragment ions (FI) in MS2, PI recorded in 
MS2, the corresponding characteristic FI in MS3, their relative intensities and the retention times (RT) in minutes (min).  
 
Metabolite ID Metabolic reaction Rat urine 
0.02 mg/kg BW 
Rat urine 
0.2 mg/kg BW 
Characteristic MS2 
fragment ions, m/z 
Relative intensity 
in MS2, % 
Characteristic MS3 
fragment ions, m/z 
Relative intensity 
in MS3, % 
RT, min 
M5 Ring-Opening + 
hydroxylation 
I I PI at m/z 316 
 
FI at m/z 191 
FI at m/z 179 
FI at m/z 173 
FI at m/z 161 









PI at m/z 121 
 
FI at m/z 93 








M8 Ring-Opening + 
carboxylation 
I I PI at m/z 330 
 
FI at m/z 295 
FI at m/z 285 
FI at m/z 208 
FI at m/z 187 









PI at m/z 121 
 
FI at m/z 93 








M17 Hydroxylation isomer 1 D D PI at m/z 420 
 
FI at m/z 385 
FI at m/z 384 
FI at m/z 209 
FI at m/z 191 








PI at m/z 385 
 
FI at m/z 209 
FI at m/z 191 
FI at m/z 173 
FI at m/z 146 
FI at m/z 133 
0 
 
64 
53 
100 
8 
92 
6.84 
 
